Kornam

Terazosin, the active ingredient in Kornam, is an alpha-1 adrenergic receptor antagonist presented as an oral tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adult patients.

GNH USA supplies Kornam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terazosin is used in cardiovascular and urological therapeutic pathways to control blood pressure and relieve prostate‑related urinary obstruction.

Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. Benign prostatic hyperplasia: relaxes smooth muscle in the prostate and bladder neck to improve urine flow. Lower urinary tract symptoms due to BPH: decreases urinary frequency and urgency associated with prostate enlargement.

Terazosin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion. - Peripheral edema. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Priapism (prolonged erection). - Acute liver injury (rare). - Allergic reactions such as rash or angioedema. - Cardiac arrhythmias in susceptible individuals. - Renal impairment exacerbation.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

Monitor blood pressure: check for orthostatic changes after the first dose. Assess renal and hepatic function: adjust therapy if impairment is present. Caution in elderly patients: increased susceptibility to hypotension. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Use with caution in patients with a history of cardiac disease. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Terazosin can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other antihypertensives (e.g., ACE inhibitors, ARBs) may cause excessive hypotension. - PDE5 inhibitors (e.g., sildenafil) increase risk of severe blood‑pressure drops. - Clonidine withdrawal when combined may precipitate hypertensive crisis.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - NSAIDs: can blunt antihypertensive effect. - Beta‑blockers: additive blood‑pressure lowering. - Lithium: possible increase in serum lithium levels. - Warfarin: monitor INR as terazosin may affect anticoagulation stability.